With most complex metabolic syndromes, diabetes and obesity have proclaimed less applicable about the classical single drug-receptor target drug development.As the "gut microbiota-host" interactions have been illuminated by molecular biology coupled with metabonomics approaches, the study strategies of therapies of chronic diseases shows increasing interest on potential utilization of traditional Chinese medicines (TCMs).